Peer-Reviewed Articles

Ray, L.A., Bujarski, S., Roche, D.J.O., Magill, M. (2018) Overcoming the “Valley of Death” in Medications Development for Alcohol Use Disorder. Alcoholism: Clinical and Experimental Research View PDF

Bujarski, S., Jentsch, J.D., Roche, D.J.O., Ramchandani, V.A., Miotto, K., & Ray, L.A. (2018). Differences in the Subjective and Motivational Properties of Alcohol across Alcohol Use Severity: Application of a Novel Translational Human Laboratory Paradigm. Neuropsychopharmacology View Accepted PDF

Bujarski, S., Lim, A., & Ray, L.A. (2018). Prevalence, Causes, and Treatment of Substance Use Disorders: A Primer. The Judge’s Journal; American Bar Association. 57(1), 10 - 15. View Accepted PDF

Ray, L.A., Green, R., Roche, D.J.O., Bujarski, S., Hartwell, E.E., Lim, A., Rohrbaugh, T., Ghahremani, D., Hutchison, K.E., & Miotto, K., (in press). Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings. Alcoholism: Clinical and Experimental Research. View PDF

Bujarski, S., Hutchison, K.E., Prause, N., & Ray, L.A. (2017). Functional Significance of Subjective Response to Alcohol across Levels of Alcohol Exposure. Addiction Biology. 22(1), 235 – 245. View PDF

Ray, L.A., Bujarski, S., Yardley, M.M., Roche, D.J.O., & Hartwell, E.E. (2017). Differences between treatment-seeking and non-treatment seeking participants in medication studies for alcoholism: Do they matter? The American Journal of Drug and Alcohol Abuse. View PDF

Ray, L.A., Bujarski, S., Shoptaw, S., Roche, D.J.O., Heinzerling, K., & Miotto, K. (2017). Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial. Neuropsychopharmacology. 42(9), 1776 – 1788. PMID: 28091532. View PDF

Roche, D.J.O., Worley, M.J., Courtney, K.E., Bujarski, S., London, E, Shoptaw, S, & Ray, L.A. (2017). Naltrexone moderates the relationship between cue-induced craving and subjective response to methamphetamine in individuals with methamphetamine use disorder. Psychopharmacology. 234(13), 1997 – 2007. View PDF

Westman, J.G., Bujarski, S., & Ray, L.A. (2016). Impulsivity Moderates Subjective Response in Alcohol Dependent Individuals. Alcohol and Alcoholism. 52(2), 249-255. View PDF

Bujarski, S., & Ray, L.A. (2016). Experimental Psychopathology Paradigms for Alcohol Use Disorders: Applications for Translational Research. Behaviour Research and Therapy. 86, 11-22. PMID: 27266992. View PDF

Green, R., Bujarski, S., Roche, D.J.O., & Ray, L.A. (2016) Relationship between Negative Affect and Smoking Topography in Heavy Drinking Smokers. Addictive Behaviors. 61, 53-57. View PDF

Ray, L.A., Bujarski, S., & Roche D.J.O. (2016) Subjective Response to Alcohol as a Research Domain Criterion. Alcoholism: Clinical and Experimental Research. 40(1), 6-17. View PDF

Bujarski, S., Hutchison, K.E., Roche, D.J.O. & Ray, L.A. (2015) Factor Structure of Subjective Responses to Alcohol in Light and Heavy Drinkers. Alcoholism: Clinical and Experimental Research. 39(7), 1193-1202. View PDF

Bujarski, S., Lau, A.S., Lee S.S., & Ray, L.A., (2015) Genetic, and Environmental Predictors of Alcohol Use in Asian American Young Adults. Journal of Studies on Alcohol and Drugs. 76(5), 690-699. Link

Hartwell, E.E., Bujarski, S., & Ray, L.A. (2015) The Association of Alcohol Severity and Metabolism with Sleep Quality in Alcohol Dependent Individuals. Alcohol and Alcoholism. 50(5), 536 – 541. View PDF

Roche, D.J.O., Bujarski, S., Hartwell, E.E., Green, R., & Ray, L.A. (2015). Combined Varenicline and Naltrexone Treatment reduces Smoking Topography Intensity in Heavy-Drinking Smokers. Pharmacology, Biochemistry and Behavior. 134, 92 – 98. View PDF

Ray, L.A., Bujarski, S., Courtney, K.E., Moallem, N.R., Lunny, K., Roche, D.J.O., Leventhal, A., Shoptaw, S., Heinzerling, K., London, E.D., & Miotto, K. (2015). The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: A Double-Blind, Placebo-Controlled, Laboratory Study. Neuropsychopharmacology. 40(10), 2347 – 2356. View PDF

Sheets, E.S., Bujarski, S., Leventhal, A., & Ray, L.A. (2015). Emotion Differentiation and Intensity during Acute Tobacco Abstinence: A Comparison of Heavy and Light Smokers. Addictive Behaviors. 47, 70-73. View PDF

Bujarski, S., Roche, D.J.O., Sheets, E.S., Krull, J.L., Guzman I., & Ray, L.A. (2015). Modeling naturalistic craving, withdrawal, and affect during early nicotine abstinence: a pilot EMA study. Experimental and Clinical Psychopharmacology. 23(2), 81 - 89. View PDF

Ray, L.A., & Bujarski, S. (2015). Mechanisms of Topiramate Effects: Refining Medications Development for Alcoholism. Addiction Biology. View PDF

Bujarski, S., & Ray, L.A. (2014). Negative Affect is Associated with Alcohol, but not Cigarette Use in Heavy Drinking Smokers, Addictive Behaviors. 39(12) 1723 - 1729. View PDF

Bujarski, S., Roche, D., Lunny, K., Moallem N., Courtney, K.E., Allen, V., Hartwell, E.E., Leventhal, A., Rohrbaugh, T., & Ray, L.A. (2014). The Relationship Between Methamphetamine and Alcohol Use in a Community Sample of Methamphetamine Users, Drug and Alcohol Dependence. 142, 127 - 132. View PDF

Bujarski, S., & Ray, L.A. (2014). Subjective Response to Intravenous Alcohol and Associated Craving in Heavy Drinkers vs. Alcohol Dependents: A Preliminary Translational Examination of Koob’s Allostatic Model in Humans. Drug and Alcohol Dependence. 140, 161 - 167. View PDF

Ashenhurst, J.R., Bujarski, S., & Ray, L.A. (2014). Modeling Behavioral Reactivity to Losses and Rewards on the Balloon Analogue Risk Task (BART): Moderation by Alcoholism Severity, Experimental and Clinical Psychopharmacology. 22(4), 298 - 306. View PDF

Roche, D.J.O., Bujarski, S., Moallem, N., Guzman, I., Shapiro, J.R., & Ray, L.A. (2014). Predictors of Smoking Lapse in a Human Laboratory Model. Psychopharmacology. 231(14), 2889 - 2897. View PDF

Ray, L.A., Bujarski, S., Squeglia, L.M., Ashenhurst, J.R., & Anton, R. (2014). Interactive Effects of OPRM1 and DAT1 Genetic Variation on Subjective Responses to Alcohol. Alcohol and Alcoholism. 49(3), 261 - 270. View PDF

Courtney, K.E., Ashenhurst, J., Bacio, G., Moallem, N., Bujarski, S., Hartwell, E. & Ray, L.A., (2013). Craving and Subjective Responses to Alcohol Administration: Validation of the Desires for Alcohol Questionnaire in the Human Lab. Journal of Studies on Alcohol and Drugs. 74(5), 797 - 802. View PDF

Ray, L.A., Sehl, M., Bujarski, S., Hutchison, K., & Enoch, M. (2013). The CRHR1 Gene, Trauma Exposure, and Alcoholism Risk: A Test of G × E Effects. Genes, Brain and Behavior 12(4), 361–369. View PDF

Ray, L.A., Lunny, K., Bujarski, S., Moallem, N., Krull, J.L. & Miotto, K. (2013). The Effects of Varenicline on Stress-Induced and Cue-Induced Craving for Cigarettes. Drug and Alcohol Dependence. 131(1–2), 136–142. View PDF

Bujarski, S., Lunny, K., & Ray, L.A. (2012). The Effects of Drinking Goal on Treatment Outcome for Alcoholism. Journal of Consulting and Clinical Psychology. 81(1), 13–22. View PDF

Ray, L.A., Bujarski, S., MacKillop J., Courtney, K.E., Monti P., & Miotto K. (2013). Subjective Response to Alcohol Among Alcohol-Dependent Individuals: Effects of the Mu-Opioid Receptor (OPRM1) Gene and Alcoholism Severity. Alcoholism: Clinical and Experimental Research. 37, E116–E124. View PDF

Ashenhurst, J.R., Bujarski, S., & Ray, L.A. (2012). Delta and Kappa Opioid Receptor Polymorphisms Influence the Effect of Naltrexone on Subjective Responses to Alcohol. Pharmacology Biochemistry and Behavior. 103(2), 253-259 View PDF

Bujarski, S., MacKillop, J., & Ray, L.A. (2012). Understanding Naltrexone Mechanism of Action and Pharmacogenetics via Behavioral Economics: A Preliminary Study. Experimental and Clinical Psychopharmacology. 20(3), 181-190 View PDF

Ray, L.A., Courtney, K.E., Bujarski, S., & Squeglia, L.M. (2012). Pharmacogenetics of Alcoholism: A Clinical Neuroscience Perspective. Pharmacogenomics. 13(2), 129-132 View PDF

Ray, L.A., Bujarski, S., Chin, P.F., & Miotto, K. (2011). Pharmacogenetics of Naltrexone in Asian Americans: A Randomized Placebo-Controlled Laboratory Study. Neuropsychopharmacology. 37(2), 445-455 View PDF

Note: All articles are the sole copyright of the respective publishers. Materials are provided for educational purposes only. Downloading of materials constitutes an agreement that the materials are for personal use only.